BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 8827067)

  • 41. Identification of the cellular protein encoded by the human Wilms' tumor (WT1) gene.
    Telerman A; Dodemont H; Degraef C; Galand P; Bauwens S; Van Oostveldt P; Amson RB
    Oncogene; 1992 Dec; 7(12):2545-8. PubMed ID: 1334252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. WT1: what has the last decade told us?
    Little M; Holmes G; Walsh P
    Bioessays; 1999 Mar; 21(3):191-202. PubMed ID: 10333728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional properties of WT1.
    Haber DA; Englert C; Maheswaran S
    Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome.
    Baird PN; Groves N; Haber DA; Housman DE; Cowell JK
    Oncogene; 1992 Nov; 7(11):2141-9. PubMed ID: 1331933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor.
    Liu JJ; Wang ZY; Deuel TF; Xu YH
    Biochem Biophys Res Commun; 1999 Jan; 254(1):197-9. PubMed ID: 9920757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein.
    Wang ZY; Qiu QQ; Gurrieri M; Huang J; Deuel TF
    Oncogene; 1995 Mar; 10(6):1243-7. PubMed ID: 7700651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
    Iben S; Royer-Pokora B
    Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features.
    Mrowka C; Schedl A
    J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S106-15. PubMed ID: 11065340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tissue-specific regulation of the WT1 locus.
    Hewitt JA; Kessler PM; Campbell CE; Williams BR
    Med Pediatr Oncol; 1996 Nov; 27(5):456-61. PubMed ID: 8827074
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database.
    Jeanpierre C; Denamur E; Henry I; Cabanis MO; Luce S; Cécille A; Elion J; Peuchmaur M; Loirat C; Niaudet P; Gubler MC; Junien C
    Am J Hum Genet; 1998 Apr; 62(4):824-33. PubMed ID: 9529364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
    Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
    Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A point mutation found in the WT1 gene in a sporadic Wilms' tumor without genitourinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome.
    Akasaka Y; Kikuchi H; Nagai T; Hiraoka N; Kato S; Hata J
    FEBS Lett; 1993 Feb; 317(1-2):39-43. PubMed ID: 8381368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.
    Rauscher FJ
    FASEB J; 1993 Jul; 7(10):896-903. PubMed ID: 8393820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Software and database for the analysis of mutations in the human WT1 gene.
    Jeanpierre C; Béroud C; Niaudet P; Junien C
    Nucleic Acids Res; 1998 Jan; 26(1):271-4. PubMed ID: 9399851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
    Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
    Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14.
    Perotti D; De Vecchi G; Testi MA; Lualdi E; Modena P; Mondini P; Ravagnani F; Collini P; Di Renzo F; Spreafico F; Terenziani M; Sozzi G; Fossati-Bellani F; Radice P
    Hum Mutat; 2004 Nov; 24(5):400-7. PubMed ID: 15459955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
    Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
    Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome.
    Kohsaka T; Tagawa M; Takekoshi Y; Yanagisawa H; Tadokoro K; Yamada M
    Hum Mutat; 1999; 14(6):466-70. PubMed ID: 10571943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A clinical overview of WT1 gene mutations.
    Little M; Wells C
    Hum Mutat; 1997; 9(3):209-25. PubMed ID: 9090524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.